Malta - engelsk - Medicines Authority

astrazeneca ab se-151 85, södertälje, sweden - budesonide, formoterol fumarate, dihydrate - pressurised inhalation, suspension - budesonide 200 µg/spray formoterol fumarate dihydrate 6 µg/spray - drugs for obstructive airway diseases

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - formoterol fumarate dihydrate, quantity: 4.5 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - long-term treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise induced asthma) in adults and children aged 12 years and over and who are receiving inhaled or oral corticosteroids and who require bronchodilator therapy.,oxis turbuhaler can be used on demand (prn) in asthmatics over the age of 18 years who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed alone by occasional use of short acting inhaled beta-2 agonists.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - formoterol fumarate dihydrate, quantity: 9 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - long-term treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise induced asthma) in adults and children aged 12 years and over and who are receiving inhaled or oral corticosteroids and who require bronchodilator therapy.,oxis turbuhaler can be used on demand (prn) in asthmatics over the age of 18 years who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed alone by occasional use of short acting inhaled beta-2 agonists.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 320 microgram; formoterol fumarate dihydrate, quantity: 9 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma rilast turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) rilast turbuhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. rilast turbuhaler is not indicated for the initiation of bronchodilator therapy in copd.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma rilast turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) rilast turbuhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. rilast turbuhaler is not indicated for the initiation of bronchodilator therapy in copd.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 80 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma rilast turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) rilast turbuhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. rilast turbuhaler is not indicated for the initiation of bronchodilator therapy in copd.

Malta - engelsk - Medicines Authority

astrazeneca ab se-151 85, södertälje, sweden - budesonide, formoterol fumarate, dihydrate - pressurised inhalation, suspension - budesonide 80 µg formoterol fumarate dihydrate 2.25 µg - drugs for obstructive airway diseases

Irland - engelsk - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - budesonide; formoterol fumarate dihydrate - inhalation powder - 200 µg/6 µg/inhalation - formoterol and budesonide

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 200 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; dilute hydrochloric acid - asthma trimbow 200/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - budesonide formoterol fumatrate dihydrate - powder for inhalation - 200/6 microgram